The European Union has awarded €6.5 million to support a multi-site randomised controlled trial of psilocybin to ease psychological and existential distress in a variety of progressive illnesses like multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD).According to the recipients, this is “the first ever European grant to fund clinical research into psychedelic-assisted…


Previous articlePT480 – Psychedelics and Consent: Power Dynamics, Boundaries, and the Concept of ‘Safe Enough’
Next articleEnsuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development and a Vision for More Equitable Drug Development